Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene) reported that its public float remains at approximately 22.22%, below the minimum level required under Rule 19A.28B of the Hong Kong Listing Rules.

The company is executing an H-Share “full circulation” programme that will convert 136.30 million unlisted shares held by 12 shareholders into H shares. The China Securities Regulatory Commission issued the filing notice on 2 April 2026, confirming completion of the filing. Jiuyuan Gene will next update filing materials and seek Hong Kong Stock Exchange approval for listing the converted shares.

Management expects the public float to rise to roughly 31.13% upon completion—restoring compliance—by the end of the second quarter of 2026, assuming no further changes in core connected shareholdings.

To prevent future shortfalls, the board is strengthening internal controls by: • adding a public-float impact check to the directors’ securities-dealing clearance process; • conducting monthly reviews of shareholding data and disclosing any potential issues promptly; • reinforcing annual director training on float requirements and securities-dealing rules; and • maintaining centralised records of treasury and repurchased shares for ongoing compliance assessments.

Jiuyuan Gene will continue to publish monthly progress updates until the public float meets the required threshold. Shareholders and potential investors are advised to exercise caution when trading the company’s shares.